Come up with a name for your new list and we'll add to it:
Enterin raised a round of funding on July 13, 2017. Investors include
New Ventures Funds.
Enterin is a biotechnology company developing novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases, such as Parkinson's disease (PD). The lead compo…